Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda Therapeutics Completes Acquisition of Civitas Therapeutics

Business Wire October 22, 2014

Acorda Therapeutics to Acquire Civitas Therapeutics

Business Wire September 24, 2014

Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on Multiple Sclerosis Therapy AMPYRA

Business Wire September 10, 2014

Acorda Therapeutics to Present at the Aegis Capital 2014 Healthcare and Technology Conference

Business Wire September 4, 2014

Acorda Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

Business Wire September 2, 2014

Acorda Therapeutics to Present at the Baird 2014 Healthcare Conference

Business Wire August 27, 2014

Acorda Therapeutics Reports Second Quarter 2014 Financial Results

Business Wire July 31, 2014

The Federal Reserve Playing Analyst Damaging to Biotechnology Companies

Accesswire July 30, 2014

Acorda Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results on July 31, 2014

Business Wire July 24, 2014

Acorda Therapeutics Announces Notification of ANDA Filing for AMPYRA®

Business Wire June 26, 2014

Acorda Therapeutics Announces Pricing of $300 Million of 1.75% Convertible Senior Notes Due 2021

Business Wire June 18, 2014

Acorda Therapeutics Announces Public Offering of Convertible Senior Notes Due 2021

Business Wire June 16, 2014

Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

Business Wire May 28, 2014

Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting

Business Wire May 27, 2014

Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer

Business Wire May 14, 2014

Acorda Therapeutics to Present at the UBS Global Healthcare Conference

Business Wire May 13, 2014

Acorda Therapeutics Named One of the Best Places to Work for in New York 2014

Business Wire May 7, 2014

Acorda Therapeutics Reports First Quarter 2014 Financial Results

Business Wire May 6, 2014

FDA Issues Complete Response Letter for PLUMIAZ(TM), Investigational Medicine for Epilepsy Cluster Seizures

Business Wire May 2, 2014

Acorda Therapeutics to Present at the Deutsche Bank's 39th Health Care Conference

Business Wire April 30, 2014